UNSPSC 51311902: Probicromil calcium

This classification denotes a mast cell stabilizer with the molecular formula C17H10O8.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0U434950BU, chemically known as 4,6-dioxo-10-propyl-4h,6h-benzo(1,2-b:5,4-b)dipyran-2,8-dicarbonsaeure but generally known as probicromil calcium, which bears US NIH Compound Identifier 71950. As of Q4 2014, PROBICROMIL CALCIUM remains the US FDA Preferred Term for this commodity. Probicromil calcium bears US NLM identifiers UMLS ID C1882465 and NCI Concept Code C66469.

SMILES: CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)[O-])C(=O)C=C(O2)C(=O)[O-].[Ca+2].

UNSPSC 51311902 Probicromil calcium is a Commodity code that in practice captures state and local procurement of pharmaceutical products and medical supplies, though recent opportunities show limited direct activity under this specific chemical compound and instead reflect broader pharmaceutical and drug-related procurement across state and local health agencies. State and local governments soliciting under related pharmaceutical codes are purchasing naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription programs to manage pharmacy benefit costs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving participating state and local facilities across multiple jurisdictions including Oregon).

Recent opportunities span Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a two-year initial contract term plus one-year renewal option; response deadline was July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed to inform future formal procurement strategy. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers with a July 1, 2026 contract effective date and evaluation weighted 75 percent on price competitiveness. Vendors must maintain cGMP and DSCSA compliance, comprehensive insurance coverage, and contractual relationships with at least two of the three authorized wholesalers.